Морфологические и иммуногистохимические особенности опухолей человека с мутацией рецептора эпидермального фактора роста
Диссертация
Впервые проведено исследование по выявлению активирующих мутаций гена ЕОРЯ у больных со светлоклеточным раком почки СевероЗападного региона РФ. Были изучены иммуногистохимические особенности аденокарцином лёгких и светлоклеточного рака почки с мутацией в гене ЕОРЯ у пациентов Северо-Западного региона РФ. Выявлены принципиальные различия в частоте и выраженности экспрессии маркеров пролиферации… Читать ещё >
Содержание
- ГЛАВА I. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. 1. Факторы прогноза при раке лёгкого
- 1. 1. 2. Рецептор эпидермального фактора роста (ЕОЫ1)
- 1. 1. 3. Кл
- 1. 1. 4. Вс
- 1. 1. 5. Р
- 1. 1. 6. Рецепторы эстрогена (ЕБ1)
- 1. 2. 1. Светлоклеточный рак почки
- 1. 2. 2. Особенности иммуногистохимической экспрессии маркеров Р-53, Вс1−2, Ю-67, ЕЯ в светлоклеточном раке почки
- Глава II. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- Глава III. РЕЗУЛЬТАТЫ СОБСТВЕННЫХ ИССЛЕДОВАНИЙ
- 3. 1. Сравнительный анализ экспрессии иммуногистохимических маркеров пролиферации и апоптоза, таргетных маркеров в аденокарциномах лёгкого с мутацией и без мутации гена ЕСЫ*
- 3. 1. 1. Клинические данные
- 3. 1. 2. Определение мутационного статуса гена ЕОИ*
- 3. 1. 3. Экспрессия К
- 3. 1. 4. Экспрессия Р
- 3. 1. 5. Экспрессия Вс
- 3. 1. 6. Экспрессия ЕЫ- а
- 3. 1. 7. Экспрессия ЕОШ
- 3. 2. Сравнительный анализ экспрессии иммуногистохимических маркеров пролиферации и апоптоза, таргетных маркеров в светлоклеточном раке почки с мутацией гена ЕСЫ
- 3. 2. 1. Клинические данные
- 3. 2. 2. Определение мутационного статуса гена ЕОБЯ
- 3. 2. 3. Экспрессия иммуногистохимических маркеров (К1−67, Р-53, Вс1−2, рецепторы эстрогена альфа) в светлоклеточном почечноклеточном раке почки с мутацией ЕвРЯ в 19 экзоне
- 3. 1. Сравнительный анализ экспрессии иммуногистохимических маркеров пролиферации и апоптоза, таргетных маркеров в аденокарциномах лёгкого с мутацией и без мутации гена ЕСЫ*
Список литературы
- Волкова, О. В. Основы гистологии с гистологической техникой / О. В. Волкова, Ю. К. Елецкий. — М.: Медицина, 1971. 272 с.
- Дьердь, К. Практическая микротехника и гистохимия / К. Дьердь. -Будапешт: Изд-во акад. наук Венгрии, 1962. — 399 с.
- Коржевский, Д. Э. Применение гематоксилина в гистологической технике / Д. Э. Коржевский // Морфология. 2007. — Т. 132, № 6. — С. 77 — 81.
- Лавдовский, М. Д. Основания к изучению микроскопической анатомии человека и животных / М. Д. Лавдовский. СПб., 1887. — 398 с.
- Лилли, Р. Патогистологическая техника и практическая гистохимия / Р. Лилли. М.: Мир, 1969. — 645 с.
- Меркулов, Г. А. Курс патогистологической техники / Г. А. Меркулов / Л.: Медицина, 1969. 340 с.
- Ромейс, Б. Микроскопическая техника / Б. Ромейс. М.: Изд-во иностранной лит., 1954. — 718 с.
- Роскин, Г. И. Микроскопическая техника / Г. И. Роскин, Л. Б. Левинсон. М.: Совет, наука, 1957. — 467 с.
- Сапожников, А. Г. Гистологическая и микроскопическая техника / А. Г. Сапожников, А. Е. Доросевич. Смоленск: САУ, 2000. — 476 с.
- Саркисов, Д. С. Микроскопическая техника: Рук. для врач, и лаборантов / Д. С. Саркисов, Ю. Л. Перов. М.: Медицина, 1996. — 468 с.
- Соболев, Л. В. Основы патолого-гистологической техники / Л. В. Соболев. СПб.:В. Безобразовъ и Ко, 1910. — 242 с.
- Фрайштат, Д. М. Реактивы и препараты для микроскопии: Справ. / Д. М. Фрайштат. -М., 1980.-480 с.
- Шацева, Т. А. Антиген Ki-67 в оценке опухолевой пролиферации. Его структура и функции / Т. А. Шацева, М. С. Мухина // Вопр. онкол.- 2004— № 2.-С. 157−164.
- Albain, K. S. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience / K. S. Albain, J. J. Crowley, M. LeBlanc et al. // J Clin Oncol.- 1991.-Vol. 9, № 9.- P. 1618−1626.
- Badalian, G. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer / G. Badalian, K. Derecskei, A. Szendroi et al. // Anticancer Res.- 2007.- Vol. 27, № 2.- P. 889−94.
- Bargonetti, J. Multiple roles of the tumor suppressor p53 / J. Bargonetti, J. J. Manfredi // Curr Opin Oncol.- 2002.- Vol. 14, № 1.- P. 86−91.
- Betticher, D. C. Prognostic significance of CCND1 (cyclin Dl) overexpression in primary resected non-small-cell lung cancer / D. C. Betticher, J. Heighway, P. S. Hasleton et al. // Brit J Cancer. 1996. — Vol. 73, № 3. — P. 294 300.
- Blons, H. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation / H. Blons, J. F. Cote, D. Le Corre et al. // Am J Surg Pathol.- 2006.- Vol. 30, № 10.- P. 1309−15.
- Bot, F. J. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters / F. J. Bot, J. C. Godschalk, K. K. Krishnadath et al. // Int J Cancer.- 1994.-Vol. 57, № 5.- P.634 -7.
- Bourdon, J. C. p53 and its isoforms in cancer / J. C. Bourdon // Brit J Cancer.- 2007.-Vol. 97, № 3.- P. 277 282.
- Bourke, W. Lung cancer in young adults / W. Bourke, D. Milstein, R. Giura et al. // Chest.- 1992.- Vol. 102, № 6. P. 1723−1729.
- Brundage, M. D. Mackillop Prognostic Factors in Non-small Cell Lung Cancer A Decade of Progress / M. D. Brundage, W. Davies // Chest. 2002. -Vol. 122, № 3. — P. 1037−1057.
- Brundage, M. D. Phase I study of a decision aid for patients with locally advanced non-small cell lung cancer / M. D. Brundage, D. Feldman-Stewart, R. Cosby et al. // J Clin Oncol.- 2001.-Vol. 19, № 5, — P. 1326−1335.
- Buccheri, G. Prognostic factors in lung cancer: tables and comments / G. Buccheri, D. Ferrigno // Eur Respir J.- 1994.- Vol. 7, № 7.- P. 1350−1364.
- Buccheri, G. Prognostic value of the tissue polypeptide antigen in lung cancer / G. Buccheri, D. Ferrigno // Chest. 1992.- Vol. 101, № 5.- P. 12 871 292.
- Bukowski, R. M. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma / R. M. Bukowski, P. Rayman, L. Molto et al. // Clin Cancer Res.- 1999.- Vol. 5, № 10.-P. 2780−9.
- Caputi, M. Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis / M. Caputi, L. De Luca, G. Papaccio et al. // Eur J Histochem.- 1997.- Vol. 41, № 2.- P. 133−138.
- Chen, L. Steroid receptors in human renal carcinoma / L. Chen, F. R. Weiss, S. Chaichik et al. // Isr J Med Sci. 1980. — Vol. 16, № 11.- P. 756−60.
- Cho, Y. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations / Y. Cho, S. Gorina, P. D. Jeffrey et al. // Science. 1994.-Vol. 265, № 5170. — P. 346−55.
- Clarke, M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview / M. Clarke // Ann Oncol. 2006. -Vol. 10, suppl. 17. — P. 59−62.
- Cohen, S. Epidermal growth factor: chemical and biological characterization / S. Cohen, J. M. Taylor // Recent Prog Horm Res. 1974- Vol. 30, № 0.-P. 2188−2194.
- Cortes-Funes, H. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients / H. Cortes-Funes, C. Gomez, R. Rosell et al. // Ann Oncol. 2005. — Vol. 16, № 7. — P. 1081- 1086.
- Couse, J. F. Estrogen receptor null mice: what have we learned and where will they lead us / J. F. Couse, K. S. Korach // Endocr Rev. 1999. — Vol. 20, № 3.-P. 35817.
- Dabbs. D.J. Diagnostic immunohistochemistry / D. J. Dabbs. Churchill Livingstone, 2002. — 828 p.
- Diez, M. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer / M. Diez, A. Torres, M.L. Maestro et al. // Brit J Cancer.- 1996 Vol. 73, № 10.-P. 1248−1254.
- Diez, M. Value of serum neuronspecific enolase in nonsmall cell lung cancer / M. Diez, A. Torres, L. Ortega et al. // Oncology (Huntingt). 1993. — Vol. 50, № 2.-P. 127−131.
- Downyard, J. Close similarity of epidermal growth factor receptor and v— erb-B oncogene protein sequences / J. Downyard, Y. Yarden, E. Mayes et al. // Nature.- 1984.-Vol. 307, № 5951. -P.521−7.
- El-Deiry, W. S. Definition of a consensus binding site for p53 / W. S. El-Deiry S. E. Kern, J. A. Pietenpol et al. // Nat Genet.- 1992.-Vol. 1, № 1.-P.45- 9.
- Ellis, R. E. Mechanisms and functions of cell death / R. E. Ellis, J. Y. Yuan, H. R. Horvitz // Ann Rev Cell Biol.-1991.-№ 7.- P. 663−98.
- Feinstein, A. R. Clinical biostatistics XIV: the purposes of prognostic stratification / A. R. Feinstein // Clin Pharmacol Ther. 1972.-Vol. -13, № 2.-P. 285−297.
- Fukuoka, M. Multi-institutional randomized phase II trial of gefltinib for previously treated patients with advanced non-small cell lung cancer / M. Fukuoka, S. Yano, G. Giaccone et al. // J Clin Oncol.- 2003.- Vol. 21, № 12.- P. 2227−9.
- Furge, K. A. Met receptor tyrosine kinase: enhanced signaling through adapter proteins / K. A. Furge, Y. W. Zhang, G. F. Vande Woude // Oncogene.-2000.- Vol. 19, № 49.-P. 5582−5589.
- Gerdes, J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic enaluations in human malignancies / J. Gerdes // Semin Cancer Biol. -1990. Vol. 1, № 3.-P. 99−206.
- Gerdes, J. Stein Producing of a mouse monoclonal antibody reactive with a human nuclear antigen associated witn cell proliferation / J. Gerdes, U. Schwab, H. Lemke // Int J Cancer.- 1983.-Vol. 31, № 1.- P. 13−20.
- Girgin, C. P53 mutations and other prognostic factors of renal cell carcinoma / C. Girgin, H. Tarhan, M. Hekimgil et al. // Urol Int.- 2001 Vol. 66, № 2 — P. 78−83.
- Gofrit, O. N. Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery / O. N. Gofrit, A. Shapiro, N. Kovalski et al. // Eur Urol.- 2001.- Vol. 39, № 6.-P. 669−74.
- Gruber, D. M. Conjugated estrogens—the natural SERMs / D. M. Gruber, J. C. Huber// Gynecol Endocrinol. -1999-Vol. 6, suppl. 13. -P. 9−12.94
- Gustafsson, J. A. What pharmacologists can learn from recent advances in estrogen signaling / J. A. Gustafsson // Trends Pharmacol Sci.-2003. Vol. 24, № 9.P. 479−485.
- Hainsworth, J. D. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib / J. D. Hainsworth, J. A. Sosman, D. R. Spigel et al. // J Clin Oncol.- 2005.- Vol. 23, № 31- P. 7889−96.
- Hall, J. M. The multifaceted mechanisms of estradiol and estrogen receptor signaling / J. M. Hall, J. F. Couse, K. S. Korach // J Biol Chem.- 2001.- Vol. 276, № 40.-P. 36 869- 36 872.
- Harada, M. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer / M. Harada, H. Dosaka-Akita, H. Miyamoto et al. // Cancer.- 1992.- Vol. 69, № 1.- P. 72−77.
- Hirata, T. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor / T. Hirata, T. Fukuse, H. Naiki et al. // Cancer Res.- 1998.- Vol. 58, № 6.-P. 1108−1110.
- Horio, Y. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer / Y. Horio, T. Takahashi, T. Kuroishi et al. // Cancer Res.- 1993.-Vol. 53, № 1.- p.
- Imyanitov, E. N. Partial restoration of degraded DNA from archival paraffin-embedded tissues / E. N. Imyanitov, M. Y. Grigoriev, V. M. Gorodinskaya et al. // Biotechniques. 2001. — Vol. 31, № 5. — P. 1000−1002.
- Ishida, H. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction / H. Ishida, K. Irie, T. Itoh et al. // Cancer. 1997. — Vol. 80, № 6.- P. 1034−45.
- Itoi, T. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients / T. Itoi, K. Yamana, V. Bilim et al. // Brit J Cancer — 2004-Vol. 90, № 1.- P. 200−205.
- Jayson, M. Increased incidence of serendipitously discovered renal cell carcinoma / M. Jayson, H. Sanders // Urology. 1998.-Vol. 51, № 2.- P. 203−5.
- Jensen, E. V. On the mechanism of estrogen action / E. V. Jensen // Perspect Biol Med.-1962.-№ 6.-P. 47−54.
- Kaghad, M. Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers / M. Kaghad, H. Bonnet, A. Yang et al. // Cell.- 1997.- Vol. 90, № 4. P. 809−819.
- Kato, S. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase / Kato S., Endoh H., Masuhiro Y., et al. // Science.-1995.-Vol. 270, № 5241.-P. 1491−1494.
- Katzel, J.A. Recent advances of novel targeted therapy in non-small cell lung cancer / J. A. Katzel, M. P. Fanucchi, Z. Li // J Hematol Oncol 2009.-№ 2—P. 2.
- Kawai, H. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer / H. Kawai, A. Ishii, K. Washiya et al. // Clin Cancer Res.-2005.-Vol. 11, № 14.-P. 5084−5089.
- Kessler, R. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer / R. Kessler, B. Gasser, G. Massard et al. // Ann Thorac Surg.- 1996.-Vol. 62, № 5.-P. 1489−1493.
- Kirkali, Z. Recent advances in kidney cancer and metastatic disease / Z. Kirkali, E. Tuzel, M. U. Mungan // Bju Int.- 2001.-Vol. 88, № 8.-P. 818−824.
- Knudson, C. M. Bcl-2 and Bax function independently to regulate cell death / C. M. Knudson, S. J. Korsmeyer // Nature Genet. 1997-Vol. 16, № 4. -P. 358−63.
- Kobayashi, S. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib / S. Kobayashi, T. J. Boggon, T. Dayaram et al. // New Engl J Med.- 2005.-Vol. 352, № 20.-P. 786−792.
- Komaki, R. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer / R. Komaki, T. Fujii, P. Perkins et al. // Int J Radiat Oncol Biol Phys.- 1996.- Vol. 36, № 3.- P.601−605.
- Komaki, R. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer / R. Komaki, L. Milas, J. Y. Ro et al. // Int J Radiat Oncol Biol Phys.- 1998.- Vol. 40, № 4.- P. 787−796.
- Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death / S. J. Korsmeyer // Blood. 1992.-Vol. 80, № 4. — P. 879−86.
- Krajewski, S. Immunohistochemical analysis of in vivo patterns of Bcl-X expression / S. Krajewski, M. Krajewska, A. Shabaik et al. // Cancer Res-1994-Vol. 54, № 21.-P. 5501−7.
- Kuiper, G. G. Cloning of a novel receptor expressed in rat prostate and ovary / G. G. Kuiper, E. Enmark, M. Pelto-Huikko et al. // Proc Natl Acad Sci USA.-1996.-Vol. 93, № 12.-P. 5925−5930.
- Lager, D. J. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma / D. J. Lager, D. D. Slagel, P. L. Palechek // Modern Pathol.- 1994.- Vol. 7, № 5.-P. 544−8.
- Langner, C. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors / C. Langner, M. Ratschek, P. Rehak et al. // J Urol.- 2004.- Vol. 171, № 2.- P. 611−4.
- Lee, J. S. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor / J. S. Lee, A. Yoon, S. K. Kalapurakal et al. // J Clin Oncol.- 1995,-Vol. 13, № 8.-P. 1893−903.
- Levine, A. J. P 53, the cellular gatekeeper for growth and division / A. J. Levine // Cell. 1997.-Vol. 88, № 3.- P. 323−331.
- Liu, M.M. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression / M. M. Liu, C. Albanese, C. M. Anderson et al. // J Biol Chem-2002- Vol. 277, № 27.-P. 24 353−24 360.
- Lynch, T. J. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib / T. J. Lynch, D. W. Bell, R. Sordella et al, // New Engl J Med.- 2004.- Vol. 350, № 21.-P. 2129−2139.
- Mackillop, W. J. The importance of prognosis in cancer medicine / W. J. Mackillop // Prognostic factors in cancer / Ed. by M. K. Gospodarowicz, D. E. Henson, R. B. P. Hutter et al. New York: Wiley & Sons, 2001. — 832 p.
- Martinez-Arribas, F. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level / F. Martinez-Arribas, T. Alvarez, G. Del Val et al. // Anticancer Res. 2007.-Vol. 27, № 1 A.- P.219−222.
- Martins, C. P. Modeling the therapeutic efficacy of p53 restoration in tumors / C. P. Martins, L. Brown-Swigart, G. I. Evan // Cell.- 2006.-Vol. 127, № 7.-P. 1323−1334.
- Maruyama, R. Absence of Bcl-2 and Fas/CD95/APO-l predicts the response to immunotherapy in metastatic renal cell carcinoma / R. Maruyama, K. Yamana, T. Itoil et al. // Brit J Cancer.- 2006.- Vol. 95, № 9.-P. 1244 1249.
- Massard, G. Bronchogenic cancer in the elderly: operative risk and long-term prognosis / G. Massard, R. Moog, J. M. Wihlm et al. // Thorac Cardiovasc Surg.- 1996.- Vol. 44, № 1.- P. 40−45.
- Massaro, D. Estrogen regulates pulmonary alveolar formation, loss, regeneration in mice / D. Massaro, G. D. Massaro // Am J Physiol Lung Cell Mol Physiol.- 2004.- Vol. 287, № 6.-P. LI 154-L1159.
- Mazel, S. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death / S. Mazel, D. Burtrum, H. T. Petrie // J Exp Med. 1996.-Vol. 183, № 5. — P. 221 926.
- Meert, A. P. EFGR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions / A. P. Meert, B. Martin, J. M. Verdebout et al. // Anticancer Res.-2006-Vol. 26, № 1A.-P. 135−8.
- Mendelson, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer / J. Mendelson, H. Baselga // J Clin Oncol-2003 .-Vol. 21, № 14.-P. 2787−99.
- Miettinen, P. J. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor / P. J. Miettinen, J. E. Berger, J. Meneses et al. // Nature.-1995.-Vol. 376, № 6538.- P. 337−341.
- Mitsudomi, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer / T. Mitsudomi, T. Oyama, T. Kusano et al. // J Natl Cancer I.- 1993.- Vol. 85, № 24.- P. 2018−2023.
- Mitsudomi, T. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent / T. Mitsudomi, S. M. Steinberg, H. K. Oie et al. // Cancer Res.- 1991.- Vol. 51, № 18.- P. 49 995 002.
- Mitsutoshi, S. Prognostic implication of Ki-67 immunostaining in treating subclinical pleural cancer found at thoracotomy in lung cancer patients / S. Mitsutoshi, K. Kimitaka, K. Hiromasa et al. // Ann Thorac Surg 2001.-Vol. 71, № 6.-P. 1765−1771.
- Mombini, H. Relationship Between Expression of p53 Protein and Tumor Subtype and Grade in Renal Cell Carcinoma / H. Mombini, G. Majid, R. Iran // Urology. -2006-Vol. 3, № 2.-P. 79−81.
- Montanaro, D. Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation / D. Montanaro, M. Maggiolini, A. G. Recchia et al. // J Mol Endocrinol.- 2005.- Vol. 35, № 2.-P. 245−256.
- Morani, A. B. R. Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice / A. B. R. Morani, O. Imamov, K. Hultenby et al. // Proc Natl Acad Sci USA.-2006.- Vol. 103, № 18.-P. 71 657 169.
- Morkve, O. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas / O. Morkve, O. J. Halvorsen, R. Skjaerven et al. // Anticancer Res. 1993. — Vol. 13, № 3.- P. 571 578.
- Motzer, R.J. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience / R J. Motzer, J. Bacik, M. Mazumdar // Clin Cancer Res. 2004. — Vol. 10, № 18.- P. 6302S-3S.
- Motzer, R. J. Renal-cell carcinoma / R. J. Motzer, N. H. Bander, D. M. Nanus // New Engl J Med.- 1996.- Vol. 335, № 12.- P. 865−75.
- Mountain, C. F. Revisions in the International System for Staging Lung Cancer / C. F. Mountain// Chest. 1997.-Vol. Ill, № 6.-P. 1710−1717.
- Murray-Zmijewski, F. P 53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress / F. Murray-Zmijewski, D. P. Lane, J. C. Bourdon // Cell Death Differ.- 2006.-Vol. 13, № 6, — P. 962−972.
- Nakano, E. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy / E. Nakano, Y. Tada, H. Fujioka et al. // J Urol.- 1984.- Vol. 132, № 2.-P. 240−5.
- Neilan, J. G. An African swine fever virus gene with similarity to the proto-oncogene bcl-2 and the Epstein-Barr virus gene BHRF1 / J. G. Neilan, Z. Lu, C. L. Afonso et al. // J Virol.-1993.-Vol. 67, № 7.- P. 4391−94.
- Normanno, N. Group NCNBC. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer / N. Normanno, M. Di Maio, E. De Maio et al. // Endocr-relat Cancer.- 2005-Vol. 12, № 4.-P. 721−747.
- Nunez, G. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines / G. Nunez, L. London, D. Hockenbery et al. // J Immunol.-1990.-Vol. 144, № 9.- P. 3602−10.
- Olive, K. P. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome / K. P. Olive, D. A. Tuveson, Z. C. Ruhe et al. // Cell.- 2004.-Vol. 119, № 6.-P. 847−60.
- Olivier, M. The IARC TP53 database: new online mutation analysis and recommendations to users / M. Olivier, R. Eeles, M. Hollstein et al. // Hum Mutat.- 2002.- Vol. 19, № 6.-P. 607−614.
- Oltvai, Z. N. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death / Z. N. Oltvai, C. L. Milliman, S. J. Korsmeyer // Cell.-1993.-Vol. 74, № 4.- P. 609−19.
- Oltvai, Z. N. Checkpoints of dueling dimers foil death wishes / Z. N. Oltvai, S. J. Korsmeyer // Cell.-1994.- Vol. 79, № 2.-P. 189−92.
- Omoto, Y. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers / Y. Omoto, Y. Kobayashi, K. Nishida et al. // Biochem Bioph Res Co.-2001.-Vol. 285, № 2.- P. 340−347.
- Paez, J. G. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy / J. G. Paez, P. A. Janne, J. C. Lee et al. // Science-2004.-Vol. 304, № 5676.-P. 1497−1500.
- Palomares, M. R. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients / M. R. Palomares, J. W. Sayre, K. C. Shekar et al. // Cancer.- 1996.- Vol. 78, № 10.- P. 2119−2126.
- Parker, A. S. Development and Evaluation of BioScore: A Biomarker Panel to Enhance Prognostic Algorithms for Clear Cell Renal Cell Carcinoma / A. S. Parker, B. C. Leibovich, M. L. Christine et al. // Cancer.- 2009.-Vol. 115, № 10.-P. 2092−2103.
- Pietras, R. J. Membraneassociated estrogen receptor signaling pathways in human cancers / R. J. Pietras, D. C. Marquez-Garbab // Clin Cancer Res.-2007-Vol. 13, № 16.-P. 4672^4676.
- Pujol, J. L. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers / J. L. Pujol, J. Simony, G. Jolimoy et al. // Brit J Cancer.- 1996.-Vol. 74, № 6.-P.964−970.
- Quinlan, D. C. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer / D. C. Quinlan, A. G. Davidson, C. L. Summers et al. // Cancer Res.- 1992.-Vol. 52, № I7.p. 4828−4831.
- Radovic, S. Non-small cell lung carcinoma: cyclin Dl, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors / S. Radovic, M. Babic, M. Doric et al. // Bosn J Basic Med Sci.- 2007.- Vol. 7, № 3.- P. 205−11.
- Renouf, D. J. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer / D. J. Renouf, R. Wood-Baker, D. N. Ionescu et al. // J Thorac Oncol.- 2009.- Vol. 4, № 4.- P. 486−91.
- Rodenhuis, S. Clinical significance of ras oncogene activation in human lung cancer / S. Rodenhuis, R. J. Slebos // Cancer Res.- 1992, — Vol. 52, № 9.- P. 2665−2669.
- Saiwaki, T. In vivo dynamics and kinetics of pKi-67: transition from a mobile to an immobile form at the onset of anaphase / T. Saiwaki, I. Kotera, M. Sasaki et al. // Exp Cell Res.- 2005.- Vol. 308, № 1, — P. 123−34.
- Salomon, D. S. Epidermal growth factor-related peptides and their receptors in human malignancies / D. S. Salomon, R. Brandt, F. Ciardiello et al. // Crit Rev Oncol Hematol.- 1995.-Vol. 19, № 3.- P. 183−232.
- Scagliotti, G. V. Prognostic significance of Ki67 labelling in resected non small cell lung cancer / G. V. Scagliotti, M. Micela, L. Gubetta et al. // Eur J Cancer. 1993.-Vol. 29A, № 3.-P. 363−5.
- Schwartz, A. G. Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex / A. G. Schwartz, G. M. Prysak, V. Murphy et al. // Clin Cancer Res. 2005.-Vol. 11, № 20.- P. 7280−7287.
- Selby, P. The value of quality of life scores in clinical cancer research / P. Selby // Eur J Cancer.- 1993.-Vol. 29A, № 12.- P.1656−1657.
- Skov, B. G. Oestrogen receptor beta overexpression in males with nonsmall cell lung cancer is associated with better survival / B. G. Skov, B. M. Fischer, H. Pappot//Lung Cancer.-2008.-Vol. 59, № l.-P. 88−94.
- Slebos, R. J. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung / R. J. Slebos, R. E. Kibbelaar, O. Dalesio et al. // New Engl J Med.- 1990.-Vol. 323, № 9.-P. 561−565.
- Sobue, T. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit / T. Sobue, T. Suzuki, I. Fujimoto et al. // Jpn J Cancer Res.- 1991.- Vol. 82, № 1.- P. 33−39.
- Takai, E. Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma / E. Takai, T. Yano, H. Iguchi et al. // Cancer-1996-Vol. 78, № 7.-P. 1384−1387.
- Thatcher, N. First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view / N. Thatcher // BMC Proc 2008-Vol.2, suppl. 2.-P. S3.
- Tungekar, M. F. Ki-67 immunostaining and survival in operable lung cancer / M. F. Tungekar, K. C. Gatter, M. S. Dunnil et al. // Histopathology-1991.-Vol. 19, № 6.-P. 545−550.
- Uchida, T. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma / T. Uchida, J. P. Gao, C. Wang et al. // Urology.- 2002.-Vol. 59, № 4.-P. 615−620.
- Vaux, D. L. Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells / D. L. Vaux, S. Cory, J. M. Adams //Nature.- 1988.-Vol. 335, № 6189.- P.44012.
- Volm, M. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas / M. Volm, W. Rittgen, P. Drings // Brit J Cancer.- 1998, — Vol. 77, № 4p. 663- 669.
- Vousden, K. H. Live or let die: the cell’s response to p53 / K. H. Vousden, X. Lu // Nat Rev Cancer.- 2002.- Vol. 2, № 8.- P. 594−604.
- Warburton, H. E. P 53 Regulation and Function in Renal Cell Carcinoma / H. E. Warburton, M. Brady, N. Vlatkovic et al. // Cancer Res.- 2005.- Vol. 65, № 15.-P. 6498−6503.
- World Cancer Report by Boyle P., IARC press, 2008.
- Wu, C. T. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers / C. T. Wu, Y. L. Chang, J. Y. Shih et al. // J Thorac Cardiovasc Surg.-2005.-Vol. 130, № 4. -P. 979−986.
- Yang, J. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer / J. Yang, N. Ramnath, K. B. Moysich et al. // BMC Cancer.- 2006.-№ 6.-P. 203.
- Yano, S. EGFR tyrosine kinase inhibitor «gefitinib (Iressa)» for cancer therapy / S. Yano, M. Yamaquchi, R. P. Donq // Nippon Yakuriqaku Zasshi-2003.-Vol. 122, № 6.-P. 491−7.
- Zigeuner, R. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue / R. Zigeuner, M. Ratschek, P. Rehak et al. // Urology. 2004 — Vol. 63, №> 4.-P. 651−5.